Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: A comparison of methotrexate resistance

Stephen E. Braun, R. Scott Mclvor, Amy S. Davidson, Mark Hanna, Christie M. Traycoff, Doug A. Berebetsky, René Gonin, Hal E. Broxmeyer, Kenneth Cornetta

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mutations in the enzyme dihydrofolate reductase (DHFR) can confer resistance to the inhibitory effects of folate analogs such as methotrexate (Mtx) and trimetrexate (Ttx). Retroviral vectors expressing the DHFR-Arg22 mutants and the newly described DHFR-Tyr22 mutant were used to transduce the hematopoietic cell line K562. In vitro selection of vector-containing cells was documented via polymerase chain reaction and Southern analysis. When proliferation of selected vector-containing cells was evaluated over a range of Mtx concentrations (0.01 to 10 μmol/L), both Arg22 and Tyr22 provided protection from Mtx, but Tyr22 proved superior to Arg22 in conferring Mtx resistance at low concentrations. Ttx proved to be 10- to 100-fold more potent than Mtx in inhibiting proliferation of nontransduced K562, but the relative effectiveness of individual mutants in conferring drug resistance was similar to that of Mtx. Decreasing the amount of folate in the culture medium to more physiological concentrations increased the potency of administered Mtx and Ttx. Drug resistance in retrovirally transduced K562 cells is consistent with the enzymatic characteristics of the individual mutants. Our findings suggest that the new Tyr22 form of DHFR may prove better in conferring drug resistance than the previously reported Arg22 mutant.

Original languageEnglish (US)
Pages (from-to)26-32
Number of pages7
JournalCancer Gene Therapy
Volume4
Issue number1
StatePublished - Dec 1 1997

Fingerprint

Tetrahydrofolate Dehydrogenase
Methotrexate
Trimetrexate
Cell Line
Genes
Drug Resistance
Folic Acid
K562 Cells
Culture Media
Polymerase Chain Reaction
Mutation
Enzymes

Keywords

  • Dihydrofolate reductase
  • Gene transfer
  • Hematopoietic cell lines
  • Methotrexate
  • Selection

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562 : A comparison of methotrexate resistance. / Braun, Stephen E.; Mclvor, R. Scott; Davidson, Amy S.; Hanna, Mark; Traycoff, Christie M.; Berebetsky, Doug A.; Gonin, René; Broxmeyer, Hal E.; Cornetta, Kenneth.

In: Cancer Gene Therapy, Vol. 4, No. 1, 01.12.1997, p. 26-32.

Research output: Contribution to journalArticle

@article{4312436a45094ee0a338dd4bc271e601,
title = "Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: A comparison of methotrexate resistance",
abstract = "Mutations in the enzyme dihydrofolate reductase (DHFR) can confer resistance to the inhibitory effects of folate analogs such as methotrexate (Mtx) and trimetrexate (Ttx). Retroviral vectors expressing the DHFR-Arg22 mutants and the newly described DHFR-Tyr22 mutant were used to transduce the hematopoietic cell line K562. In vitro selection of vector-containing cells was documented via polymerase chain reaction and Southern analysis. When proliferation of selected vector-containing cells was evaluated over a range of Mtx concentrations (0.01 to 10 μmol/L), both Arg22 and Tyr22 provided protection from Mtx, but Tyr22 proved superior to Arg22 in conferring Mtx resistance at low concentrations. Ttx proved to be 10- to 100-fold more potent than Mtx in inhibiting proliferation of nontransduced K562, but the relative effectiveness of individual mutants in conferring drug resistance was similar to that of Mtx. Decreasing the amount of folate in the culture medium to more physiological concentrations increased the potency of administered Mtx and Ttx. Drug resistance in retrovirally transduced K562 cells is consistent with the enzymatic characteristics of the individual mutants. Our findings suggest that the new Tyr22 form of DHFR may prove better in conferring drug resistance than the previously reported Arg22 mutant.",
keywords = "Dihydrofolate reductase, Gene transfer, Hematopoietic cell lines, Methotrexate, Selection",
author = "Braun, {Stephen E.} and Mclvor, {R. Scott} and Davidson, {Amy S.} and Mark Hanna and Traycoff, {Christie M.} and Berebetsky, {Doug A.} and Ren{\'e} Gonin and Broxmeyer, {Hal E.} and Kenneth Cornetta",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "26--32",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562

T2 - A comparison of methotrexate resistance

AU - Braun, Stephen E.

AU - Mclvor, R. Scott

AU - Davidson, Amy S.

AU - Hanna, Mark

AU - Traycoff, Christie M.

AU - Berebetsky, Doug A.

AU - Gonin, René

AU - Broxmeyer, Hal E.

AU - Cornetta, Kenneth

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Mutations in the enzyme dihydrofolate reductase (DHFR) can confer resistance to the inhibitory effects of folate analogs such as methotrexate (Mtx) and trimetrexate (Ttx). Retroviral vectors expressing the DHFR-Arg22 mutants and the newly described DHFR-Tyr22 mutant were used to transduce the hematopoietic cell line K562. In vitro selection of vector-containing cells was documented via polymerase chain reaction and Southern analysis. When proliferation of selected vector-containing cells was evaluated over a range of Mtx concentrations (0.01 to 10 μmol/L), both Arg22 and Tyr22 provided protection from Mtx, but Tyr22 proved superior to Arg22 in conferring Mtx resistance at low concentrations. Ttx proved to be 10- to 100-fold more potent than Mtx in inhibiting proliferation of nontransduced K562, but the relative effectiveness of individual mutants in conferring drug resistance was similar to that of Mtx. Decreasing the amount of folate in the culture medium to more physiological concentrations increased the potency of administered Mtx and Ttx. Drug resistance in retrovirally transduced K562 cells is consistent with the enzymatic characteristics of the individual mutants. Our findings suggest that the new Tyr22 form of DHFR may prove better in conferring drug resistance than the previously reported Arg22 mutant.

AB - Mutations in the enzyme dihydrofolate reductase (DHFR) can confer resistance to the inhibitory effects of folate analogs such as methotrexate (Mtx) and trimetrexate (Ttx). Retroviral vectors expressing the DHFR-Arg22 mutants and the newly described DHFR-Tyr22 mutant were used to transduce the hematopoietic cell line K562. In vitro selection of vector-containing cells was documented via polymerase chain reaction and Southern analysis. When proliferation of selected vector-containing cells was evaluated over a range of Mtx concentrations (0.01 to 10 μmol/L), both Arg22 and Tyr22 provided protection from Mtx, but Tyr22 proved superior to Arg22 in conferring Mtx resistance at low concentrations. Ttx proved to be 10- to 100-fold more potent than Mtx in inhibiting proliferation of nontransduced K562, but the relative effectiveness of individual mutants in conferring drug resistance was similar to that of Mtx. Decreasing the amount of folate in the culture medium to more physiological concentrations increased the potency of administered Mtx and Ttx. Drug resistance in retrovirally transduced K562 cells is consistent with the enzymatic characteristics of the individual mutants. Our findings suggest that the new Tyr22 form of DHFR may prove better in conferring drug resistance than the previously reported Arg22 mutant.

KW - Dihydrofolate reductase

KW - Gene transfer

KW - Hematopoietic cell lines

KW - Methotrexate

KW - Selection

UR - http://www.scopus.com/inward/record.url?scp=0030639412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030639412&partnerID=8YFLogxK

M3 - Article

C2 - 9012448

AN - SCOPUS:0030639412

VL - 4

SP - 26

EP - 32

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -